Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Thymoma 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Metastatic Solid Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 10belinostat 2Plicamycin 2Decitabine 2Celecoxib 2tocilizumab 1spartalizumab 1obinutuzumab 1naptumomab estafenatox 1epacadostat 1entinostat 1durvalumab 1alvocidib 1Tetrahydrouridine 1Tablets 1Surgical Procedures, Operative 1Quality of Life 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1Immunotherapy, Adoptive 1Immunotherapy 1Immunoenzyme Techniques 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × FANG vaccine × Other solid neoplasm × Clear all
NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡